Medmen Enterprises (OTCMKTS:MMNFF) and Cumberland Pharmaceuticals (NASDAQ:CPIX) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, valuation, dividends, analyst recommendations, risk, profitability and earnings.
This is a summary of recent ratings and target prices for Medmen Enterprises and Cumberland Pharmaceuticals, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Earnings & Valuation
This table compares Medmen Enterprises and Cumberland Pharmaceuticals’ revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Cumberland Pharmaceuticals||$40.74 million||2.26||-$6.96 million||($0.12)||-49.58|
Medmen Enterprises has higher earnings, but lower revenue than Cumberland Pharmaceuticals.
Insider & Institutional Ownership
32.3% of Cumberland Pharmaceuticals shares are held by institutional investors. 39.4% of Cumberland Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
This table compares Medmen Enterprises and Cumberland Pharmaceuticals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Medmen Enterprises beats Cumberland Pharmaceuticals on 5 of the 8 factors compared between the two stocks.
About Medmen Enterprises
MedMen Enterprises Inc., together with its subsidiaries, operates as a cannabis company in the United States. The company cultivates, produces, and distributes, and retails recreational and medicinal cannabis. As of November 1, 2018, it had licenses for 69 retail stores; and 17 cultivation and production facilities across 12 states. The company is headquartered in Culver City, California.
About Cumberland Pharmaceuticals
Cumberland Pharmaceuticals Inc., a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products for hospital acute care, gastroenterology, and oncology markets in the United States and internationally. It offers Acetadote, an injection for the treatment of acetaminophen poisoning; Caldolor, an injection for the treatment of pain and fever; Kristalose, a prescription laxative, for the treatment of chronic and acute constipation; Omeclamox-Pak for the treatment of Helicobacter pylori infection and duodenal ulcer disease; Vaprisol injection for treating hyponatremia; Ethyol injection for the reduction of xerostomia; Totect injection, for emergency oncology intervention, to treat the toxic effects of anthracycline chemotherapy; and Vibativ injection, for the treatment of certain serious bacterial infections. The company's Phase II product candidates includes Hepatoren injection for the treatment of critically ill patients suffering from liver and kidney failure; Boxaban oral capsules for the treatment of asthma patients; Vasculan oral capsule for the treatment of systemic sclerosis; and Portaban for the treatment of portal hypertension. It also develops RediTrex injection for the treatment of active rheumatoid, juvenile idiopathic, and severe psoriatic arthritis, as well as severe disabling psoriasis. The company markets and sells its products through sales representatives and district managers. Cumberland Pharmaceuticals Inc. has a strategic alliance with Clinigen Group plc and Nordic Group B.V. The company was incorporated in 1999 and is headquartered in Nashville, Tennessee.
Receive News & Ratings for Medmen Enterprises Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medmen Enterprises and related companies with MarketBeat.com's FREE daily email newsletter.